Rosen, Neal

Publications

Sort by

Co-Author Network

selected publications

Combined inhibition of KRAS^G12C and mTORC1 kinase is synergistic in non-small cell lung cancer. Nature communications. 2024 Academic Article GET IT
Diet induced insulin resistance is due to induction of PTEN expression. 2024 GET IT
Tumor-agnostic genomic and clinical analysis of BRAF fusions identify actionable targets. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Academic Article GET IT
Intermittent MEK inhibition with GITR co-stimulation rescues T-cell function for increased efficacy with CTLA-4 blockade in solid tumor models. Cancer immunology research. 2024 Academic Article GET IT
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer. 2024 GET IT
A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation. Cancer discovery. 2024 Academic Article GET IT
Tumorigenesis driven by the BRAF^V600E oncoprotein requires secondary mutations that overcome its feedback inhibition of migration and invasion. 2024 GET IT
BRAF - a tumour-agnostic drug target with lineage-specific dependencies. Nature reviews. Clinical oncology. 2024 Review GET IT
Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer. Cancer discovery. 2023 Academic Article GET IT
Times cited: 41
Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation. Cancer discovery. 2022 Academic Article GET IT
Times cited: 13
Targeting Oncogenic RAS Protein. The New England journal of medicine. 2022 Editorial Article GET IT
Times cited: 1
ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Molecular cell. 2022 Academic Article GET IT
Times cited: 11
Anatomic position determines oncogenic specificity in melanoma. Nature. 2022 Academic Article GET IT
Times cited: 4
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. JTO clinical and research reports. 2021 Academic Article GET IT
Times cited: 8
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature communications. 2021 Academic Article GET IT
Times cited: 49
Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. 2021 GET IT
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer discovery. 2021 Academic Article GET IT
Times cited: 79
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nature communications. 2021 Academic Article GET IT
Times cited: 16
Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. 2021 GET IT
Finally, Effective Inhibitors of Mutant KRAS. The New England journal of medicine. 2021 Editorial Article GET IT
Times cited: 6
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. Nature chemical biology. 2021 Academic Article GET IT
Times cited: 38
Anti-tumor effects of an ID antagonist with no observed acquired resistance. NPJ breast cancer. 2021 Academic Article GET IT
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 20
Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Molecular cell. 2021 Academic Article GET IT
Times cited: 68
KRAS ^G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 23
Mutant-selective degradation by BRAF-targeting PROTACs. Nature communications. 2021 Academic Article GET IT
Times cited: 80
Targeted drug delivery strategies for precision medicines. Nature reviews. Materials. 2021 Academic Article GET IT
Times cited: 503
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 30
EGFR Blockade Reverts Resistance to KRAS^G12C Inhibition in Colorectal Cancer. Cancer discovery. 2020 Academic Article GET IT
Times cited: 267
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors. Molecular oncology. 2020 Academic Article GET IT
Times cited: 27
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer discovery. 2020 Academic Article GET IT
Times cited: 172
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 37
Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2. Cancer research. 2020 Academic Article GET IT
Times cited: 11
The sixth international RASopathies symposium: Precision medicine-From promise to practice. American journal of medical genetics. Part A. 2019 Conference Paper GET IT
Times cited: 25
Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 83
Global view of the RAF-MEK-ERK module and its immediate downstream effectors. Scientific reports. 2019 Academic Article GET IT
Times cited: 11
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer cell. 2019 Academic Article GET IT
Times cited: 136
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. Cancer discovery. 2019 Academic Article GET IT
Times cited: 29
Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Academic Article GET IT
Times cited: 240
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. 2019 GET IT
Times cited: 63
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nature medicine. 2018 Academic Article GET IT
Times cited: 132
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer cell. 2018 Academic Article GET IT
Times cited: 298
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018 Academic Article GET IT
Times cited: 26
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer discovery. 2018 Academic Article GET IT
Times cited: 95
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer cell. 2018 Academic Article GET IT
Times cited: 560
Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer discovery. 2017 Academic Article GET IT
Times cited: 249
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer discovery. 2017 Academic Article GET IT
Times cited: 285
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer research. 2017 Academic Article GET IT
Times cited: 66
A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature. 2017 Academic Article GET IT
Times cited: 77
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017 Academic Article GET IT
Times cited: 391
An approach to suppress the evolution of resistance in BRAF^V600E-mutant cancer. Nature medicine. 2017 Academic Article GET IT
Times cited: 125
PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 40
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro-oncology. 2017 Academic Article GET IT
Times cited: 79
Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. The Journal of investigative dermatology. 2017 Academic Article GET IT
Times cited: 20
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2016 Academic Article GET IT
Times cited: 279
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer immunology research. 2016 Academic Article GET IT
Times cited: 135
Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 103
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. BMC cancer. 2016 Academic Article GET IT
Times cited: 24
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 79
A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Academic Article GET IT
Times cited: 311
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016 Academic Article GET IT
Times cited: 349
The Walking Speed Questionnaire: Assessing Walking Speed in a Self-reported Format. Journal of orthopaedic trauma. 2016 Academic Article GET IT
Times cited: 8
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science (New York, N.Y.). 2016 Academic Article GET IT
Times cited: 490
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 10
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer discovery. 2015 Academic Article GET IT
Times cited: 400
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 269
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer cell. 2015 Academic Article GET IT
Times cited: 368
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer. 2015 Academic Article GET IT
Times cited: 28
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. Cancer discovery. 2015 Academic Article GET IT
Times cited: 180
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. The oncologist. 2015 Academic Article GET IT
Times cited: 55
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Science translational medicine. 2015 Academic Article GET IT
Times cited: 270
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer cell. 2015 Academic Article GET IT
Times cited: 255
Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015 Academic Article GET IT
Times cited: 376
Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 235
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer cell. 2014 Academic Article GET IT
Times cited: 201
The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. Nature cell biology. 2014 Academic Article GET IT
Times cited: 97
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 2014 Academic Article GET IT
Times cited: 148
SOS1 and Ras regulate epithelial tight junction formation in the human airway through EMP1. EMBO reports. 2014 Academic Article GET IT
Times cited: 18
Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged. Cancer cell. 2014 Article GET IT
Times cited: 38
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer discovery. 2014 Academic Article GET IT
Times cited: 116
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 107
PTEN is a protein tyrosine phosphatase for IRS1. Nature structural & molecular biology. 2014 Academic Article GET IT
Times cited: 100
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer cell. 2014 Academic Article GET IT
Times cited: 240
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014 Academic Article GET IT
Times cited: 159
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 41
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer research. 2014 Academic Article GET IT
Times cited: 247
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer discovery. 2014 Academic Article GET IT
Times cited: 155
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 98
Towards a unified model of RAF inhibitor resistance. Cancer discovery. 2014 Academic Article GET IT
Times cited: 37
Tumor adaptation and resistance to RAF inhibitors. Nature medicine. 2013 Information Resource GET IT
Times cited: 380
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Science translational medicine. 2013 Academic Article GET IT
Times cited: 234
ERK pathway inhibitors: how low should we go?. Cancer discovery. 2013 Academic Article GET IT
Times cited: 35
Image based feasibility of renal sparing surgery for very low risk unilateral Wilms tumors: a report from the Children's Oncology Group. The Journal of urology. 2013 Academic Article GET IT
Times cited: 34
Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer research. 2013 Academic Article GET IT
Times cited: 126
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 118
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer discovery. 2013 Comment GET IT
Times cited: 315
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer cell. 2012 Academic Article GET IT
Times cited: 437
Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Science signaling. 2012 Academic Article GET IT
Times cited: 47
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 178
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer discovery. 2012 Academic Article GET IT
Times cited: 241
Inhibition of mycobacterial infection by the tumor suppressor PTEN. The Journal of biological chemistry. 2012 Academic Article GET IT
Times cited: 36
Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imaging. Molecular imaging. 2012 Academic Article GET IT
Times cited: 13
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer discovery. 2012 Academic Article GET IT
Times cited: 95
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 31
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Academic Article GET IT
Times cited: 1212
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. The Journal of clinical investigation. 2011 Academic Article GET IT
Times cited: 307
Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. The Journal of experimental medicine. 2011 Academic Article GET IT
Times cited: 100
Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer research. 2011 Academic Article GET IT
Times cited: 57
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer discovery. 2011 Academic Article GET IT
Times cited: 371
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer cell. 2011 Academic Article GET IT
Times cited: 987
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 315
Resistance to BRAF inhibition in melanomas. The New England journal of medicine. 2011 Academic Article GET IT
Times cited: 183
Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 18
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 269
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011 Academic Article GET IT
Times cited: 443
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 180
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer cell. 2011 Academic Article GET IT
Times cited: 819
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 35
Targeted cancer therapies. Chinese journal of cancer. 2011 Editorial Article GET IT
Times cited: 63
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer research. 2010 Academic Article GET IT
Times cited: 142
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 391
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer cell. 2010 Academic Article GET IT
Times cited: 350
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 123
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer biology & therapy. 2010 Academic Article GET IT
Times cited: 59
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010 Academic Article GET IT
Times cited: 1509
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer research. 2010 Academic Article GET IT
Times cited: 206
Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magnetic resonance in medicine. 2009 Academic Article GET IT
Times cited: 18
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene. 2009 Academic Article GET IT
Times cited: 104
Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 58
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 505
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer research. 2009 Academic Article GET IT
Times cited: 159
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 173
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 42
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). Journal of neuro-oncology. 2008 Academic Article GET IT
Times cited: 140
Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer research. 2008 Academic Article GET IT
Times cited: 218
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Molecular cancer therapeutics. 2008 Academic Article GET IT
Times cited: 103
Models from experiments: combinatorial drug perturbations of cancer cells. Molecular systems biology. 2008 Academic Article GET IT
Times cited: 159
The heat shock protein 90 chaperone complex: an evolving therapeutic target. Current cancer drug targets. 2008 Information Resource GET IT
Times cited: 47
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PloS one. 2008 Academic Article GET IT
Times cited: 250
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. The Journal of clinical endocrinology and metabolism. 2008 Academic Article GET IT
Times cited: 111
Determinants of RASistance to anti-epidermal growth factor receptor agents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Editorial Article GET IT
Times cited: 63
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer research. 2008 Academic Article GET IT
Times cited: 160
Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nature biotechnology. 2008 Academic Article GET IT
Times cited: 92
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 164
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer research. 2007 Academic Article GET IT
Times cited: 60
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 293
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PloS one. 2007 Academic Article GET IT
Times cited: 106
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proceedings of the National Academy of Sciences of the United States of America. 2007 Academic Article GET IT
Times cited: 449
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 194
Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. Molecular and cellular endocrinology. 2007 Academic Article GET IT
Times cited: 8
Targeting HER2 in prostate cancer: where to next?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Editorial Article GET IT
Times cited: 31
An acetylation site in the middle domain of Hsp90 regulates chaperone function. Molecular cell. 2007 Academic Article GET IT
Times cited: 358
AKT and cancer--is it all mTOR?. Cancer cell. 2006 Comment GET IT
Times cited: 54
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2006 Academic Article GET IT
Times cited: 45
Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer research. 2006 Academic Article GET IT
Times cited: 75
Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2006 Academic Article GET IT
Times cited: 158
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer research. 2006 Academic Article GET IT
Times cited: 2237
Hsp90: a novel target for cancer therapy. Current topics in medicinal chemistry. 2006 Information Resource GET IT
Times cited: 149
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 2005 Academic Article GET IT
Times cited: 266
BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2005 Academic Article GET IT
Times cited: 1178
Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2005 Academic Article GET IT
Times cited: 300
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer cell. 2005 Academic Article GET IT
Times cited: 368
Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. Journal of medicinal chemistry. 2005 Academic Article GET IT
Times cited: 163
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 114
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Applied immunohistochemistry & molecular morphology : AIMM. 2005 Academic Article GET IT
Times cited: 22
Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. The Journal of urology. 2004 Conference Paper GET IT
Times cited: 4
Development of a fluorescence polarization assay for the molecular chaperone Hsp90. Journal of biomolecular screening. 2004 Academic Article GET IT
Times cited: 85
New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target. Journal of the American Chemical Society. 2004 Academic Article GET IT
Times cited: 156
Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chemistry & biology. 2004 Academic Article GET IT
Times cited: 157
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nature biotechnology. 2004 Academic Article GET IT
Times cited: 273
General method for the synthesis of 8-arylsulfanyl adenine derivatives. The Journal of organic chemistry. 2004 Academic Article GET IT
Times cited: 24
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer research. 2003 Academic Article GET IT
Times cited: 59
Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorganic & medicinal chemistry letters. 2003 Academic Article GET IT
Times cited: 47
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer research. 2003 Academic Article GET IT
Times cited: 88
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proceedings of the National Academy of Sciences of the United States of America. 2003 Academic Article GET IT
Times cited: 88
Development of purine-scaffold small molecule inhibitors of Hsp90. Current cancer drug targets. 2003 Information Resource GET IT
Times cited: 94
Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR. Chemistry & biology. 2003 Academic Article GET IT
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 2003 Academic Article GET IT
Times cited: 416
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer research. 2003 Academic Article GET IT
Times cited: 273
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 111
Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol. Angewandte Chemie (International ed. in English). 2003 Academic Article GET IT
Times cited: 74
Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002. Breast cancer research and treatment. 2003 Conference Paper GET IT
17AAG: low target binding affinity and potent cell activity--finding an explanation. Molecular cancer therapeutics. 2003 Academic Article GET IT
Times cited: 154
Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorganic & medicinal chemistry. 2002 Academic Article GET IT
Times cited: 190
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 2002 Academic Article GET IT
Times cited: 261
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. The Journal of biological chemistry. 2002 Academic Article GET IT
Times cited: 518
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Cancer research. 2002 Academic Article GET IT
Times cited: 150
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 420
The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer. Breast cancer research and treatment. 2002 Academic Article GET IT
Times cited: 17
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 173
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene. 2002 Academic Article GET IT
Times cited: 252
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer research. 2001 Academic Article GET IT
Times cited: 337
Facile synthesis of a library of 9-alkyl-8-benzyl-9H-purin-6-ylamine derivatives. Journal of combinatorial chemistry. 2001 Academic Article GET IT
Times cited: 29
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer research. 2001 Academic Article GET IT
Times cited: 499
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 160
LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorganic & medicinal chemistry letters. 2001 Academic Article GET IT
Times cited: 45
Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer research. 2001 Academic Article GET IT
Times cited: 137
A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chemistry & biology. 2001 Academic Article GET IT
Times cited: 258
Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer. Prostate cancer and prostatic diseases. 2001 Academic Article GET IT
Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer research. 2000 Academic Article GET IT
Times cited: 130
Synthesis and evaluation of geldanamycin-testosterone hybrids. Bioorganic & medicinal chemistry letters. 2000 Academic Article GET IT
Times cited: 83
Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer research. 2000 Academic Article GET IT
Times cited: 90
A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. Cancer chemotherapy and pharmacology. 2000 Academic Article GET IT
Times cited: 16
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer research. 1999 Academic Article GET IT
Times cited: 117
Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. Breast cancer research and treatment. 1999 Academic Article GET IT
Times cited: 41
Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proceedings of the National Academy of Sciences of the United States of America. 1999 Academic Article GET IT
Times cited: 177
Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorganic & medicinal chemistry letters. 1999 Academic Article GET IT
Times cited: 102
The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells. Prostate cancer and prostatic diseases. 1999 Academic Article GET IT
Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. The Journal of biological chemistry. 1998 Academic Article GET IT
Times cited: 435
A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. The Journal of biological chemistry. 1998 Academic Article GET IT
Times cited: 105
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proceedings of the National Academy of Sciences of the United States of America. 1998 Academic Article GET IT
Times cited: 201
ras Mutation: does it have clinical import?. The cancer journal from Scientific American. 1997 Article GET IT
Times cited: 1
Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell. 1997 Academic Article GET IT
Times cited: 1189
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proceedings of the National Academy of Sciences of the United States of America. 1996 Academic Article GET IT
Times cited: 379
Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene. 1996 Academic Article GET IT
Times cited: 63
Refining the origins of breast cancer. Nature medicine. 1995 Comment GET IT
Times cited: 1
Identification of a novel repressive element in the proximal lck promoter. The Journal of biological chemistry. 1995 Academic Article GET IT
Times cited: 11
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer research. 1995 Academic Article GET IT
Times cited: 400
Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells. Journal of cellular physiology. 1995 Academic Article GET IT
Times cited: 27
Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. The Journal of biological chemistry. 1995 Academic Article GET IT
Times cited: 188
Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. The Journal of clinical investigation. 1995 Academic Article GET IT
Times cited: 381
Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research. 1994 Academic Article GET IT
Times cited: 32
The molecular basis for cellular transformation: implications for esophageal carcinogenesis. Seminars in oncology. 1994 Information Resource GET IT
Times cited: 7
A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene. 1994 Academic Article GET IT
Times cited: 98
p53Val135 temperature sensitive mutant suppresses growth of human breast cancer cells. Breast cancer research and treatment. 1994 Academic Article GET IT
Times cited: 5
Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression. Molecular endocrinology (Baltimore, Md.). 1992 Academic Article GET IT
Times cited: 125
Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer research. 1991 Academic Article GET IT
Times cited: 192
The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer. Cancer treatment and research. 1991 Information Resource GET IT
Times cited: 57
General assay for phosphoproteins in cerebrospinal fluid: a candidate marker for paraneoplastic cerebellar degeneration. Annals of neurology. 1990 Academic Article GET IT
Times cited: 2
Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. The Journal of clinical investigation. 1990 Academic Article GET IT
Times cited: 166
Insulin-like growth factor receptor expression and function in human breast cancer. Cancer research. 1990 Academic Article GET IT
Times cited: 316
Modulation of EGF receptor expression by differentiating agents in human colon carcinoma cell lines. Cancer communications. 1990 Academic Article GET IT
Times cited: 28
Identification of an alternate type I insulin-like growth factor receptor beta subunit mRNA transcript. The Journal of biological chemistry. 1989 Academic Article GET IT
Times cited: 43
Expression of insulin-like growth factor-II mRNA in fetal kidney and Wilms' tumor. An in situ hybridization study. Laboratory investigation; a journal of technical methods and pathology. 1989 Academic Article GET IT
Times cited: 30
Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. The Journal of biological chemistry. 1989 Academic Article GET IT
Times cited: 196
Selective expression of alternative lck mRNAs in human malignant cell lines. Molecular and cellular biology. 1989 Academic Article GET IT
Times cited: 34
Coordinate alteration of pp60c-src abundance and c-src RNA expression in human neuroblastoma variants. Oncogene. 1989 Academic Article GET IT
Times cited: 12
Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Molecular endocrinology (Baltimore, Md.). 1989 Academic Article GET IT
Times cited: 390
The insulin-like growth factor binding protein BP-25 is expressed by human breast cancer cells. Biochemical and biophysical research communications. 1989 Academic Article GET IT
Times cited: 55
Alterations in the expression of pp60c-src and p56lck associated with butyrate-induced differentiation of human colon carcinoma cells. Oncogene research. 1989 Academic Article GET IT
Times cited: 46
Insulin-like growth factor II mRNA expression in human breast cancer. Cancer research. 1988 Academic Article GET IT
Times cited: 229
Analysis of pp60c-src tyrosine kinase activity and phosphotyrosyl phosphatase activity in human colon carcinoma and normal human colon mucosal cells. Journal of cellular biochemistry. 1987 Academic Article GET IT
Times cited: 31
Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer research. 1987 Academic Article GET IT
Times cited: 285
Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines. Oncogene research. 1987 Academic Article GET IT
Times cited: 96
Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. Journal of cellular biochemistry. 1987 Information Resource GET IT
Times cited: 109
Analysis of pp60c-src in human colon carcinoma and normal human colon mucosal cells. Oncogene research. 1987 Academic Article GET IT
Times cited: 74
Analysis of the c-src gene product structure, abundance, and protein kinase activity in human neuroblastoma and glioblastoma cells. Oncogene research. 1987 Academic Article GET IT
Times cited: 25
Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. The Journal of biological chemistry. 1986 Academic Article GET IT
Times cited: 200
Increased N-myc expression following progressive growth of human neuroblastoma. Cancer research. 1986 Academic Article GET IT
Times cited: 40
Increased pp60c-src tyrosyl kinase activity in human neuroblastomas is associated with amino-terminal tyrosine phosphorylation of the src gene product. Proceedings of the National Academy of Sciences of the United States of America. 1985 Academic Article GET IT
Times cited: 99
Properties of protein kinase and adenylate cyclase-deficient variants of a macrophage-like cell line. Journal of cellular physiology. 1979 Academic Article GET IT
Times cited: 17
Genetic approaches to the mechanism of macrophage functions. Federation proceedings. 1978 Academic Article GET IT
Times cited: 9
Inhibition of plasminogen activator secretion by cyclic AMP in a macrophage-like cell line. Journal of cyclic nucleotide research. 1978 Academic Article GET IT
Times cited: 11
Modulation of Fc-mediated phagocytosis by cyclic AMP and insulin in a macrophage-like cell line. Journal of immunology (Baltimore, Md. : 1950). 1977 Academic Article GET IT
Times cited: 44
Isolation of variants in phagocytosis of a macrophage-like continuous cell line. The Journal of experimental medicine. 1977 Academic Article GET IT
Times cited: 35

more ...

less ...

Background

education and training

M.D., Albert Einstein College of Medicine of Yeshiva University 79
Ph.D., Yeshiva University 79
A.B., Columbia University 1971

Contact

full name

Neal Rosen

primary email

rosenn@mskcc.org

VIVO Weill Cornell Medical College

Neal Rosen Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email